Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)
The objectives of this study are to evaluate the efficacy and safety of sotatercept (MK-7962) treatment (plus background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus background PAH therapy) at 24 weeks in…
- Trial name
- NCT04576988
- Testing
- Sotatercept, Background PAH Therapy
- Where
- 120 sites in United States, Argentina and 19 more
- Volunteers
- 324 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Artery Hypertension, Congenital Heart Disease
Heart Catheterization Using Magnetic Resonance Imaging (MRI) Fluoroscopy and Passive Guidewires
Background: A heart catheterization is a diagnostic heart procedure used to measure pressures and take pictures of the blood flow through the heart chambers.
- Conditions
- Pulmonary Artery Hypertension, Congenital Heart Disease, Structural Heart Disease
- Trial name
- NCT03152773
- Testing
- MRI Heart guidewire catheterization
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Pharmacogenomics in Pulmonary Arterial Hypertension
Our goal is to determine clinically in Pulmonary Arterial Hypertension patients if associations exist between the efficacy and toxicity of sitaxsentan, bosentan, and ambrisentan and several gene polymorphisms in several key…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, PAH WHO Group I
- Trial name
- NCT00593905
- Testing
- Sitaxsentan, Bosentan, Ambrisentan
- Where
- United States
- Sponsor
- West Penn Allegheny Health System
Hypertension, Pulmonary
Efficacy and Safety of Ambrisentan in Children 8-18yrs
A 6-month (24-week), randomized, open label evaluation of the safety, tolerability, and efficacy of a high and low dose ambrisentan (adjusted for body weight) treatment group in subjects aged 8 years up to 18 years with pulmonary…
- Trial name
- NCT01332331
- Testing
- Ambrisentan - low dose, Ambrisentan - high dose
- Where
- 24 sites in United States, Argentina and 7 more
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension
Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to see if Lung LLC's new experimental formulation of the medicine Beraprost Sodium, called Beraprost Sodium 314d Modified Release (BPS-314d-MR), can improve the symptoms of pulmonary arterial…
- Trial name
- NCT01966302
- Testing
- BPS-314d-MR
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Pulmonary Arterial Hypertension
[18F]FES PET/CT in PAH
In this study positron emission tomography (PET/CT) imaging will be used to evaluate evaluation of estrogen receptor heterogeneity and functionality in Pulmonary Arterial Hypertension (PAH) using the investigational radiotracer…
- Trial name
- NCT02899533
- Testing
- [18F] FES
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pennsylvania
Pulmonary Arterial Hypertension
Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients
Previous studies suggest that combinations of existing therapies may be effective for pulmonary arterial hypertension (PAH). However, all of these studies are sequential combination therapy, for example, by adding sildenafil to…
- Trial name
- BIPH (NCT01712997)
- Testing
- Iloprost, Bosentan
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Air Force Military Medical University, China
Heart Defects, Congenital, Pulmonary Arterial Hypertension
Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions
Pulmonary arterial hypertension (PAH) in patients with congenital heart disease (CHD) is associated with considerable morbidity and even mortality.
- Conditions
- Heart Defects, Congenital, Pulmonary Arterial Hypertension, Genetic Testing
- Trial name
- NCT02691689
- Testing
- Genetic testing
- Where
- Belgium
- Volunteers
- 21 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Sickle Cell Disease
Epidemiology and Pathophysiological Mechanisms of HTAP in SS and SC Children in Martinique and Guadeloupe.
pulmonary arterial hypertension (PAH) has been reported with a prevalence of approximately 30% in adult sickle cell disease (SCD) patients, with an increased mortality in SCD patients with PAH, compared with those without PAH.
- Trial name
- SAPOTILLE (NCT03368261)
- Testing
- HTAP/ clinical complications in the sickle cell disease
- Where
- Martinique
- Volunteers
- 185 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Sleep-Disordered Breathing, Pulmonary Arterial Hypertension
Sleep Disordered Breathing in Precapillary Pulmonary Hypertension: Effect of CPAP Treatment
Evaluation of the effect of CPAP (continuous positive airway pressure ) treatment in PAH (pulmonary arterial hypertension) and CTEPH (chronic thromboembolic pulmonary hypertension) patients suffering from sleep disordered…
- Conditions
- Sleep-Disordered Breathing, Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT02583906
- Testing
- CPAP
- Where
- Belgium
- Volunteers
- 8 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Pulmonary Arterial Hypertension
Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension
Pulmonary hypertension is a rare condition that leads to right ventricular dysfunction and premature death. Only modest improvements of outcomes have been observed with the current available advanced specific drug therapy.
- Trial name
- DENERV'AP (NCT02525926)
- Testing
- denervation
- Where
- 5 sites in France
- Volunteers
- 1 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of…
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
- Trial name
- NCT05462574
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Vanderbilt University Medical Center
Primary Pulmonary Hypertension
Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
The primary objective of this study is to evaluate the long-term safety and tolerability of LIQ861, a dry powder formulation of treprostinil, in patients with Pulmonary Arterial Hypertension (PAH).
- Trial name
- INSPIRE (NCT03399604)
- Testing
- LIQ861 Inhaled Treprostinil
- Where
- 38 sites in United States
- Volunteers
- 121 people
- Sponsor
- Liquidia Technologies, Inc.
Connective Tissue Diseases, Pulmonary Hypertension
Prevalence of Pulmonary Arterial Hypertension in Patients With Connective Tissue Diseases in Egyptian Patients
Measuring the incidence and prevalence of PAH in Egyptian patients with different types of MCD Determination of survival \& the risk factors of mortality.
- Trial name
- NCT02768259
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University
Systemic Sclerosis, Scleroderma
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
The purpose of this study is to determine the timeline of progression from pre-pulmonary hypertension to diagnosable pulmonary hypertension based on right heart catheterization.
- Conditions
- Systemic Sclerosis, Scleroderma, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- Trial name
- NCT00377949
- Where
- 25 sites in United States
- Volunteers
- 602 people
- Sponsor
- Georgetown University
Hypertension, Pulmonary
Insulin Resistance in Pulmonary Arterial Hypertension
The purpose of this study is to evaluate 1) the incidence of insulin resistance (a pre-diabetic state) in patients with pulmonary hypertension, and 2) test the utility of a validated PH therapy (Tracleer) versus Pioglitazone in…
- Trial name
- NCT00825266
- Testing
- bosentan, Pioglitazone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Stanford University
Scleroderma, Systemic, Lung Diseases, Interstitial
Functional Exercise Tests in Patients With Systemic Sclerosis
The aim of the study is to examine the validity of peripheral oxygen saturation measurement during the 6-minute walk test in patients with Systemic Sclerosis (SSc) and to examine the utility of two other functional tests as…
- Conditions
- Scleroderma, Systemic, Lung Diseases, Interstitial, Pulmonary Arterial Hypertension, Acroosteolysis
- Trial name
- NCT04650659
- Testing
- 6-minute walk test part one, 6-minute walk test part two, 1-minute sit-to-stand test
- Where
- Denmark
- Volunteers
- 83 people
- Sponsor
- University of Aarhus
PAH, CTEPH
Effects of Pulmonary Rehabilitation on Quality of Life and Health in Pulmonary Arterial Hypertension Patients
Pulmonary hypertension (PH) is a major global health concern, affecting approximately 1% of the world's population. With global aging and increased life expectancy, its incidence continues to rise.
- Trial name
- EPRQoL-PAH (NCT06973382)
- Testing
- Comprehensive Pulmonary Rehabilitation Program, Standard Pulmonary Rehabilitation
- Volunteers
- 84 people
- Sponsor
- Beijing Chao Yang Hospital
Pulmonary Arterial Hypertension
Tezosentan in Pulmonary Arterial Hypertension
Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With Stable, Chronic Pulmonary Arterial…
- Trial name
- NCT01077297
- Testing
- Tezosentan
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 3 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Pulmonary Arterial Hypertension
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
This is an international, multicenter, randomized, double-blind, placebo-controlled, event driven study in subjects with pulmonary arterial hypertension.
- Trial name
- FREEDOM-EV (NCT01560624)
- Testing
- Treprostinil Diolamine
- Where
- 155 sites in United States, Argentina and 21 more
- Volunteers
- 690 people
- Sponsor
- United Therapeutics